Malaysian (KLSE) Pharma Industry Analysis
UpdatedJul 26, 2024
DataAggregated Company Financials
Companies6
- 7D-1.7%
- 3M-8.3%
- 1Y-0.4%
- YTDn/a
Over the last 7 days, the Pharma industry has dropped 1.7%, driven by pullbacks from every company within the industry. Over the last year, the industry has been flat overall. As for the next few years, earnings are forecast to decline by 16% per annum.
Industry Valuation and Performance
Has the Malaysian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|
Loading
Current Industry PE
- Investors are pessimistic on the Malaysian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 8.1x which is lower than its 3-year average PE of 14.9x.
- The industry is trading close to its 3-year average PS ratio of 1.8x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have grown 48% per year over the last three years.
- Revenues for these companies have grown 9.5% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does Malaysian Pharma compare with similar industries?
| MY Market | -1.65% | |
| Healthcare | -1.76% | |
| Pharma | -1.69% | |
| Pharma | -1.69% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| No data available | |||||